Surface modification of neurovascular stents: from bench to patient
Student AuthorsChristopher T. Zoppo
Document TypeJournal Article
MetadataShow full item record
AbstractFlow-diverting stents (FDs) for the treatment of cerebrovascular aneurysms are revolutionary. However, these devices require systemic dual antiplatelet therapy (DAPT) to reduce thromboembolic complications. Given the risk of ischemic complications as well as morbidity and contraindications associated with DAPT, demonstrating safety and efficacy for FDs either without DAPT or reducing the duration of DAPT is a priority. The former may be achieved by surface modifications that decrease device thrombogenicity, and the latter by using coatings that expedite endothelial growth. Biomimetics, commonly achieved by grafting hydrophilic and non-interacting polymers to surfaces, can mask the device surface with nature-derived coatings from circulating factors that normally activate coagulation and inflammation. One strategy is to mimic the surfaces of innocuous circulatory system components. Phosphorylcholine and glycan coatings are naturally inspired and present on the surface of all eukaryotic cell membranes. Another strategy involves linking synthetic biocompatible polymer brushes to the surface of a device that disrupts normal interaction with circulating proteins and cells. Finally, drug immobilization can also impart antithrombotic effects that counteract normal foreign body reactions in the circulatory system without systemic effects. Heparin coatings have been explored since the 1960s and used on a variety of blood contacting surfaces. This concept is now being explored for neurovascular devices. Coatings that improve endothelialization are not as clinically mature as anti-thrombogenic coatings. Coronary stents have used an anti-CD34 antibody coating to capture circulating endothelial progenitor cells on the surface, potentially accelerating endothelial integration. Similarly, coatings with CD31 analogs are being explored for neurovascular implants.
SourceZoppo CT, Mocco J, Manning NW, Bogdanov AA Jr, Gounis MJ. Surface modification of neurovascular stents: from bench to patient. J Neurointerv Surg. 2023 Oct 4:jnis-2023-020620. doi: 10.1136/jnis-2023-020620. Epub ahead of print. PMID: 37793794.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/52766
Rights© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.